drugset
drugset / Trial / NCT05059743

ADME Study of [14C]- Larotinib in Healthy Male Subjects

NCT05059743 ↗

Phase 1 Completed 6 enrolled Sunshine Lake Pharma Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]-Larotinib（Z650）in healthy male subjects.

Timeline

Start
2021-11-20
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Larotinib Unknown 350 mg Oral

Indications

No indication recorded.